Abstract
Purpose
Testicular seminomas occur in young men and are highly curable. Toxicities following treatment for men with extensive stage II-III seminomas may cause long-term morbidities. However, it is not clear whether the risk of late effects also increases following surgery for testis-confined seminoma. In this systematic review, we examined the available literature regarding the incidence of late effects in our target population of patients with stage I seminoma treated with orchidectomy alone.
Method
Publications were identified through an electronic literature search using the MEDLINE, EMBASE and PsychInfo databases, identifying cohorts treated for stage I seminoma. Data on late effects were collected and classified as physical or psychological.
Results
Six hundred and four articles were screened to identify 100 studies. In the target population, available evidence suggests no increased risk of cardiovascular disease, metabolic syndrome, or renal dysfunction compared to the general population. Sperm counts were initially lower than an age-matched cohort; however, counts normalised when re-assessed 5 years later. Data were not specifically reported for the target population regarding bone health, second malignancy, hypogonadism, fertility and all psychological domains. Heterogeneity of study design and reporting methods contributed to uncertainty regarding the true incidence and clinical significance of late effects.
Conclusions
The curability of stage I seminoma and the wide range of potential late effects of treatment suggest the need for long-term monitoring alongside standard cancer surveillance. Important data are needed on the prevalence of late effects, specifically related to testicular cancer survivors undergoing surveillance following orchidectomy.
Implications for cancer survivors
Awareness and screening for relevant late effects may prevent further morbidity in men treated for stage I seminoma.
Similar content being viewed by others
References
Australian Institute of Health and Welfare (AIHW) (2017) Australian Cancer Incidence and Mortality (ACIM) books: testicular cancer. AIHW, Canberra <http://aihw.gov.au/acim-books>
Gilbert DC, Van As NJ, Huddart RA (2009) Reducing treatment toxicities in the management of good prognosis testicular germ cell tumors. Expert Rev Anticancer Ther 9(2):223–233
Znaor A, Lortet-Tieulent J, Jemal A, Bray F (2014) International variations and trends in testicular cancer incidence and mortality. Eur Urol 65(6):1095–1106
Beard CJ, Gupta S, Motzer RJ, O’Donnell EK, Plimack ER, Margolin KA, Ryan CJ, Sheinfeld J, Feldman DR (2015) Follow-up management of patients with testicular cancer: a multidisciplinary consensus-based approach. J Natl Compr Cancer Netw 13(6):811–822
Warde PGM (2009) Evolving concepts in stage I seminoma. BJU Int 104:1357–1361
Dong W, Gang W, Liu M, Zhang H (2016) Analysis of the prognosis of patients with testicular seminoma. Oncol Lett 11(2):1361–1366
Travis LBBC, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer D, Miller RC, Gietema JA, van Leeuwen FE, Williams JP, Nichols CR, Einhorn LH, Fossa SD (2010) Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 102:1114–1130
Kvammen OTM, Solberg A, Møller B, Klepp OH, Fosså S, Tandstad T (2017) Long-term causes of relative excess mortality after diagnosis of testicular germ cell tumor. J Clin Oncol 35(suppl; abstr 4553):4553
Lubberts SKL, Steggink LC, Steursma G, Nuver J, Oosting S, van Ginkel RJ, de Jong IJ, Eulenburg C, Lefrandt JD, Meijer C, Sluiter WJ, Gietema JA (2017) Life expectancy 20 years after cisplatin-based treatment for testicular cancer (TC). J Clin Oncol 35(suppl; abstr 4550):4550
Peckham MJBA, Liew KH, Horwich A, Robinson B, Dobbs HJ, McElwain TJ, Hendry WF (1983) The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). Br J Cancer 1983(47):613–619
Gilligan T (2011) Testicular cancer survivorship. Hematol Oncol Clin North Am 25(3):627–639
Pearce SM, Liauw SL, Eggener SE (2015) Management of low-stage testicular seminoma. Urol Clin North Am 42(3):287–298
Glaser SM, Vargo JA, Balasubramani GK, Beriwal S (2016) Surveillance and radiation therapy for stage I seminoma-have we learned from the evidence? Int J Radiat Oncol Biol Phys 94(1):75–84
Huddart RA, Norman A, Moynihan C, Horwich A, Parker C, Nicholls E, Dearnaley DP (2005) Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 93(2):200–207
LA Moher D, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269
Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.handbook.cochrane.org. Accessed 15 June 2018
Fosså SD, Aass N, Harvei S, Tretli S (2004) Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer 90(3):607–612
van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PTR, Schimmel EC, Aleman BMP, van Leeuwen FE (2006) Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol Off J Am Soc Clin Oncol 24(3):467–475
Willemse PM, Hamdy NAT, De Kam ML, Burggraaf J, Osanto S (2014) Changes in bone mineral density in newly diagnosed testicular cancer patients after anticancer treatment. J Clin Endocrinol Metab 99(11):4101–4108
Murugaesu N, Powles T, Bestwick J, Oliver RTD, Shamash J (2009) Long-term follow-up of testicular cancer patients shows no predisposition to osteoporosis. Osteoporos Int 20(9):1627–1630
Ondrusova M, Ondrus D, Dusek L, Spanikova B (2009) Damage of hormonal function and bone metabolism in long-term survivors of testicular cancer. Neoplasma 56(6):473–479
Sagstuen H, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Wilsgaard T, Bremnes RM (2005) Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol Off J Am Soc Clin Oncol 23(22):4980–4990
Fosså SD, Chen J, Schonfeld SJ, McGlynn KA, McMaster ML, Gail MH et al (2005) Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst 97(14):1056–1066
Ondrus D, Ondrusova M, Friedova L (2014) Second malignancies in long-term testicular cancer survivors. Int Urol Nephrol 46(4):749–756
van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, Noyon R, Eliel MR, van Kerkhoff EH, Delemarre JF, Somers R (1993) Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol Off J Am Soc Clin Oncol 11(3):415–424
Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE et al (1997) Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89(19):1429–1439
Travis LB, Fosså SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H et al (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97(18):1354–1365
Hansen PV, Trykker H, Helkjoer PE, Andersen J (1989) Testicular function in patients with testicular cancer treated with orchiectomy alone or orchiectomy plus cisplatin-based chemotherapy. J Natl Cancer Inst 81(16):1246–1250
Fosså SD, Aabyholm T, Vespestad S, Norman N, Ous S (1993) Semen quality after treatment for testicular cancer. Eur Urol 23(1):172–176
Brydoy M, Fosså SD, Klepp O, Bremnes RM, Wist EA, Bjoro T et al (2012) Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer. Br J Cancer 107(11):1833–1839
Ping P, Gu B-H, Li P, Huang Y-R, Li Z (2014) Fertility outcome of patients with testicular tumor: before and after treatment. Asian J Androl 16(1):107–111
Huyghe E, Matsuda T, Daudin M, Chevreau C, Bachaud J-M, Plante P, Bujan L, Thonneau P (2004) Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 100(4):732–737
Brydøy M, Fosså SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Dahl O (2005) Paternity following treatment for testicular cancer. J Natl Cancer Inst 97(21):1580–1588
Thonneau P, Marchand S, Tallec A, Ferial ML, Ducot B, Lansac J, Lopes P, Tabaste JM, Spira A (1991) Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988–1989). Hum Reprod 6(6):811–816
Kim C, McGlynn KA, McCorkle R, Li Y, Erickson RL, Ma S et al (2012) Sexual functioning among testicular cancer survivors: a case-control study in the U.S. J Psychosom Res 73(1):68–73
Dahl AA, Bremnes R, Dahl O, Klepp O, Wist E, Fosså SD (2007) Is the sexual function compromised in long-term testicular cancer survivors? Eur Urol 52(5):1438–1447
Arai Y, Kawakita M, Okada Y, Yoshida O (1997) Sexuality and fertility in long-term survivors of testicular cancer. J Clin Oncol Off J Am Soc Clin Oncol 15(4):1444–1448
Beard CJ, Travis LB, Chen M-H, Arvold ND, Nguyen PL, Martin NE, Kuban DA, Ng AK, Hoffman KE (2013) Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. Cancer 119(15):2771–2777
Nord C, Bjøro T, Ellingsen D, Mykletun A, Dahl O, Klepp O, Bremnes RM, Wist E, Fosså SD (2003) Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 44(3):322–328
Sprauten M, Brydøy M, Haugnes HS, Cvancarova M, Bjøro T, Bjerner J, Fosså SD, Oldenburg J (2014) Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. J Clin Oncol Off J Am Soc Clin Oncol 32(6):571–578
Hansen SW, Berthelsen JG, von der Maase H (1990) Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J Clin Oncol Off J Am Soc Clin Oncol 8(10):1695–1698
Pühse G, Secker A, Kemper S, Hertle L, Kliesch S (2011) Testosterone deficiency in testicular germ-cell cancer patients is not influenced by oncological treatment. Int J Androl 34(5 Pt 2):e351–e3e7
O’Carrigan B, Fournier M, Olver IN, Stockler MR, Whitford H, Toner GC, Thomson DB, Davis ID, Hanning F, Singhal N, Underhill C, Clingan P, McDonald A, Boland A, Grimison P, Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2014) Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort study. Intern Med J 44(8):813–817
Nuver J, Smit AJ, Wolffenbuttel BHR, Sluiter WJ, Hoekstra HJ, Sleijfer DT, Gietema JA (2005) The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol Off J Am Soc Clin Oncol 23(16):3718–3725
Rossen P, Pedersen AF, Zachariae R, von der Maase H (2012) Sexuality and body image in long-term survivors of testicular cancer. Eur J Cancer 48(4):571–578
Tuinman MA, Fleer J, Sleijfer DT, Hoekstra HJ, Hoekstra-Weebers JEHM (2005) Marital and sexual satisfaction in testicular cancer survivors and their spouses. Support Care Cancer 13(7):540–548
Alacacioglu A, Ulger E, Varol U, Yavuzsen T, Akyol M, Yildiz Y et al (2014) Sexual satisfaction, anxiety, depression and quality of life in testicular cancer survivors. Med Oncol 31(7):43
Rieker PP, Fitzgerald EM, Kalish LA, Richie JP, Lederman GS, Edbril SD, Garnick MB (1989) Psychosocial factors, curative therapies, and behavioral outcomes. A comparison of testis cancer survivors and a control group of healthy men. Cancer 64(11):2399–2407
Gritz ER, Wellisch DK, Siau J, Wang HJ (1990) Long-term effects of testicular cancer on marital relationships. Psychosomatics 31(3):301–312
Grov EK, Fosså SD, Bremnes RM, Dahl O, Klepp O, Wist E et al (2009) The personality trait of neuroticism is strongly associated with long-term morbidity in testicular cancer survivors. Acta Oncol 48(6):842–849
Smith ABRC, Butow P et al (2018) A systematic review of quantitative observational studies investigating psychological distress in testicular cancer survivors. Psycho-Oncology 27(5):1129–1138
Rieker PP, Edbril SD, Garnick MB (1985) Curative testis cancer therapy: psychosocial sequelae. J Clin Oncol Off J Am Soc Clin Oncol 3(8):1117–1126
Eberhard J, Ståhl O, Cohn-Cedermark G, Cavallin-Ståhl E, Giwercman Y, Rastkhani H, Rylander L, Eberhard-Gran M, Kvist U, Giwercman A (2010) Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality. J Affect Disord 122(3):260–266
Thorsen L, Nystad W, Stigum H, Dahl O, Klepp O, Bremnes RM, Wist E, Fosså SD (2005) The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Support Care Cancer 13(8):637–646
Thorsen L, Nystad W, Dahl O, Klepp O, Bremnes RM, Wist E et al (2003) The level of physical activity in long-term survivors of testicular cancer. Eur J Cancer 39(9):1216–1221
Rutskij R, Gaarden T, Bremnes R, Dahl O, Finset A, Fossa SD, Klepp O, Sorebo O, Wist E, Dahl AA (2010) A study of coping in long-term testicular cancer survivors. Psychol Health Med 15(2):146–158
Rudberg L, Nilsson S, Wikblad K (2000) Health-related quality of life in survivors of testicular cancer 3 to 13 years after treatment. J Psychosoc Oncol 18(3):19–31
Tuinman MA, Fleer J, Hoekstra HJ, Sleijfer DT, Hoekstra-Weebers JEHM (2004) Quality of life and stress response symptoms in long-term and recent spouses of testicular cancer survivors. Eur J Cancer 40(11):1696–1703
Rossen PB, Pedersen AF, Zachariae R, von der Maase H (2009) Health-related quality of life in long-term survivors of testicular cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(35):5993–5999
Shinn EH, Swartz RJ, Thornton BB, Spiess PE, Pisters LL, Basen-Engquist KM (2010) Testis cancer survivors’ health behaviors: comparison with age-matched relative and demographically matched population controls. J Clin Oncol Off J Am Soc Clin Oncol 28(13):2274–2279
Kim C, McGlynn KA, McCorkle R, Erickson RL, Niebuhr DW, Ma S et al (2011) Quality of life among testicular cancer survivors: a case-control study in the United States. Qual Life Res Int J Qual Life Asp Treat Care Rehab 20(10):1629–1637
Stuart NS, Woodroffe CM, Grundy R, Cullen MH (1990) Long-term toxicity of chemotherapy for testicular cancer—the cost of cure. Br J Cancer 61(3):479–484
Fleer J, Hoekstra HJ, Sleijfer DT, Tuinman MA, Klip EC, Hoekstra-Weebers JEHM (2006) Quality of life of testicular cancer survivors and the relationship with sociodemographics, cancer-related variables, and life events. Support Care Cancer 14(3):251–259
Alanee S, Russo P (2012) Suicide in men with testis cancer. Eur J Cancer Care 21(6):817–821
Fosså SD, de Wit R, Roberts JT, Wilkinson PM, de Mulder PHM, Mead GM, Cook P, de Prijck L, Stenning S, Aaronson NK, Bottomley A, Collette L, European Organization for Research and Treatment of Cancer Genitourinary Group 30941, Medical Research Council Testicular Cancer Study Group TE20 (2003) Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol Off J Am Soc Clin Oncol 21(6):1107–1118
Stouten-Kemperman MM, de Ruiter MB, Caan MWA, Boogerd W, Kerst MJ, Reneman L, Schagen SB (2015) Lower cognitive performance and white matter changes in testicular cancer survivors 10 years after chemotherapy. Hum Brain Mapp 36:4638–4647
Skaali T, Fosså SD, Andersson S, Cvancarova M, Langberg CW, Lehne G, Dahl AA (2011) Self-reported cognitive problems in testicular cancer patients: relation to neuropsychological performance, fatigue, and psychological distress. J Psychosom Res 70(5):403–410
Amidi A, Wu LM, Pedersen AD, Mehlsen M, Pedersen CG, Rossen P, Agerbæk M, Zachariae R (2015) Cognitive impairment in testicular cancer survivors 2 to 7 years after treatment. Support Care Cancer 23(10):2973–2979
Schagen SB, Boogerd W, Muller MJ, Huinink WTB, Moonen L, Meinhardt W et al (2008) Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol 47(1):63–70
Pedersen AD, Rossen P, Mehlsen MY, Pedersen CG, Zachariae R, von der Maase H (2009) Long-term cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc 15(2):296–301
Acknowledgements
IDD is supported by a National Health and Medical Research Council Practitioner Fellowship (APP1102604).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
ESM 1
(DOCX 62 kb)
Rights and permissions
About this article
Cite this article
Soon, J.A., Anton, A., Torres, J. et al. Exploring the spectrum of late effects following radical orchidectomy for stage I testicular seminoma: a systematic review of the literature. Support Care Cancer 27, 373–382 (2019). https://doi.org/10.1007/s00520-018-4492-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-018-4492-7